

Servier factsheet

Founded to serve health, Servier is a global pharmaceutical group governed by a non-profit Foundation. We aspire to have a meaningful social impact, both for patients and for a sustainable world. This unique governance model enables us to fully serve our vocation with a long-term vision: being committed to therapeutic progress to serve patient needs.

34th

largest pharmaceutical worldwide group

2nd

largest French pharmaceutical group

5th

leading pharmaceutical group in cardiology worldwide*

5,3Mds €
revenue

over 70%
of our R&D investments are dedicated to oncology

Around 97%
of the active ingredients used in the Group's brand-name medicines are produced by Servier in France

61

projects in pipeline, 36 of which in development and 25 research projects (as of January 2024)

21,900

employees as of September 2023

over 150

countries where the Group's medicines are distributed

14th/40

Servier ranks 14 in the 2023 Patient View ranking among pharmaceutical groups working with associations of patients

2nd

place in the 2023 Patient View ranking among pharmaceutical groups working with associations of patients in oncology

12

international or european associations of patients have worked with Servier in 2023

*IQVIA, Analytics Link / World 75 countries – MAT Q3-2024

Our therapeutic areas



With an extensive range of brand-name and generic medicines, Servier helps to treat patients in over 150 countries.

Oncology

Cancer is the second leading cause of death in the world* and numbers are on the rise. To address the growing need for therapeutic solutions, we have made oncology and in particular hard-to-treat cancers a priority focus for development.

Cardiometabolism and venous diseases

We intend to maintain our leading position in this area by taking a strategic and innovative approach to managing the life cycle of our medicines in particular by developing *Single Pill Combinations* (SPC: treatments that combine several active ingredients in a single pill)

Neuroscience

We focus our R&D efforts on developing new medicines that slow the progression of rare diseases or diseases with a genetic origin that affect sub-populations of patients.

Immuno-inflammation

We develop targeted therapies to correct the inappropriate immune response through different approaches such as:

- ⇒ targeting a protein that plays a role in the pathology
- ⇒ targeting various adaptive immune system mechanisms, which could stop the production of autoantibodies that drive disease.

*Source : WHO

The strategy we defined for the period through to 2030 is both realistic and bold. It addresses the health challenges of today and tomorrow and fulfils our vocation as a Group committed to therapeutic progress to serve patient needs.

BY 2030, SERVIER AIMS TO BE:



An innovative and patient-driven company with a rich pipeline



A resilient, growing and highly profitable company, balanced across three pillars: oncology, neuroscience & immuno-inflammation, cardiometabolism & venous diseases, and Generics



A company with a measurable positive social impact



An attractive company, with proud and passionate employees

OUR AMBITION IS UNDERPINNED BY THE FOLLOWING TARGETS:



Launch one new indication or medicine per year in each therapeutic area



Achieve €8 billion in revenue and EBITDA exceeding 30%



Reduce our scope 1 & 2 emissions by 42% as compared to 2021/2022
40% women in Group governance bodies



Obtain an international HR certification award in each Group entity